With just over two months left in 2022, due to the normalization of centralized procurement and medical insurance negotiations, the transformation of the pharmaceutical industry is still accelerating, and pharmaceutical executives are leaving
.
On the evening of October 18, Zhongheng Group issued an announcement that the company's directors Lin Yifei and Jiang Yadong, and the company's supervisor Shi Zhongbo submitted a written letter of resignation, and the three no longer held any position
in the company.
According to the announcement, all three resigned
due to job adjustments.
On October 17, Luban Pharmaceutical issued an announcement that the company's board of directors received the resignation report submitted by director Mr.
Li Bonan, on October 15, 2022, and the resignation will take effect
from the date of election of new directors at the general meeting of shareholders.
The above-mentioned resignation personnel will not hold other positions
in the company after their resignation.
On October 14, Yite Medical announced that Li Zhenglin, a director of the company, resigned and will no longer hold other positions in the company after his resignation, and at the same time, the company's board of directors nominated Wei Sunming, executive deputy general manager of Changshake Venture Capital, to take over
.
On October 10, Hengrui Pharmaceutical announced that the company's board of directors recently received a resignation report from Tao Weikang, deputy general manager of the company, and after resigning from the above position due to personal reasons, Tao Weikang will no longer hold any position
in the company.
At the same time, it was announced that He Feng was appointed as the deputy general manager
of Hengrui Pharmaceutical.
On October 9, Yifan Pharmaceutical issued an announcement that Wang Jie, vice president of the company, submitted a written resignation report and would resign as vice president of Yifan Pharmaceutical and would not hold any position
in the company and its subsidiaries.
Also on the 9th, Meinian Health announced that the company's board of directors recently received a written resignation report
submitted by Lin Qing, vice president and secretary of the board of directors of the company.
Lin Qing applied to resign from the position of vice president and secretary of the board of directors of the company for personal reasons, and no longer held any position
in the company after resignation.
In addition, Boyalife announced on October 9 that the company's board of directors received a resignation report from Zhang Shifang, a member of the company's party committee and vice president, on October 8, and Zhang Shifang applied for resignation
due to personal reasons.
Zhang Shifang will no longer hold any position
in the company after his resignation.
.
.
.
.
.
.
From the perspective of departure, most of the executives of pharmaceutical companies resigned for personal reasons, which also reflects the impact of changes in the industry policy environment and internal structure adjustment on executives, as well as the trend of transformation and upgrading, change innovation and accelerated flow of talents in China's pharmaceutical industry
.
The major change of executives of many pharmaceutical companies has attracted attention
in the industry.
For example, Hengrui Pharmaceutical's new R&D executive, He Feng, worked for Bristol-Myers Squibb, Novartis and AbbVie, engaged in the research and development of innovative drugs in the field of viruses, cancer, kidney disease and other diseases, and then joined Shanghai Hengrui Pharmaceutical Co.
, Ltd.
as deputy general manager in 2015, and in 2022, he served as CEO of Shanghai Hengrui Pharmaceutical Co.
, Ltd.
, where he has been engaged in R&D in the pharmaceutical industry for more than 20 years
.
In addition to He Feng, in May this year, Hengrui Pharmaceutical announced that Dai Hongbin, former deputy general manager with 22 years of experience in operation and management, will be promoted to general manager; In April, Hengrui Pharmaceutical appointed Zhang Xiaojing as deputy general manager and chief medical executive officer (oncology), and Wang Quan as deputy general manager to jointly promote the company's clinical research and development work
.
Behind the frequent personnel adjustments of Hengrui, the industry believes that the company's transformation is imminent, and the change of senior executives is also a relevant decision
made on the current transformation.
The industry believes that the "major change of blood" of management is only a microcosm
of the frequent changes of executives in the pharmaceutical industry today.
According to statistics, since the beginning of 2022, more than 300 executives in the pharmaceutical industry have announced their departures, and an average of 1 pharmaceutical company executive will leave
every day.
Among them, there are many executives in Greater China of multinational pharmaceutical companies, management of traditional pharmaceutical companies, and R&D leaders and founders of biopharmaceutical companies
.
Some analysts believe that 2022 is a key year to determine the future trend of China's pharmaceutical industry, and the demand for core talents in the emerging pharmaceutical track will become greater and greater in the future, and the competition for talents will become more intense
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
